Live Breaking News & Updates on Molecular International Prognostic Scoring System

Stay updated with breaking news from Molecular international prognostic scoring system. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Genomic data optimizes hematopoietic stem-cell transplantation (HSCT) timing for myelodysplastic syndromes (MDS) and improves patient outcomes

1. A decision support system using the Molecular International Prognostic Scoring System (IPSS-M) can optimize the timing of HSCT for MDS patients. 2. Patients with low and moderate-low risk MDS benefit from delayed HSCT, while those with higher risks benefit from immediate HSCT under the IPSS-M model. Evidence Rating Level: 2 (Good) Study Rundown: The ....

United States , Molecular International Prognostic Scoring System , Rating Level ,

Orca-T Shows Promise in Intermediate-/High-Risk MDS

The stem cell thrapy, Orca-T led to promising relapse-free and overall survival rates in patients with intermediate- to high-risk myelodysplastic syndrome. ....

United States , Arpita Gandhi , American Society Of Hematology Annual Meeting , Molecular International Prognostic Scoring System , Oregon Health , Division Of Hematology Medical Oncology , Science University , International Expert Panel , School Of Medicine , Hematology Annual , Medical Oncology , Expert Panel ,

Orca-T Shows High Survival Rates in Intermediate-/High-Risk Myelodysplastic Syndrome

The high-precision cell therapy Orca-T demonstrated high rates of relapse-free survival, overall survival, and graft-vs-host disease RFS at 1 year, as well as a low incidence of GVHD in patients with intermediate- to high-risk myelodysplastic syndrome. ....

United States , Arpita Gandhi , Science University , International Expert Panel , Division Of Hematology Medical Oncology , Molecular International Prognostic Scoring System , Oregon Health , School Of Medicine , Medical Oncology , Expert Panel , Treatment With Orca T , Patients With Hematologic Cancers , Graft Vs Host Disease , Myelodysplastic Syndrome ,

Allogeneic HCT Provides OS Benefit Independent of TP53 Allelic Status in MDS

Patients with myelodysplastic syndrome harboring a TP53 mutation experienced a survival benefit with allogeneic hematopoietic cell transplantation compared with non-HCT treatment regardless of TP53 allelic status. ....

Marrow Transplant Clinical Trials Network , International Prostate Symptom Score , Molecular International Prognostic Scoring System , Blood Cells , Design Cells , Myelodysplastic Syndromes ,

Allogeneic HCT Provides OS Benefit Independent of TP53 Allelic Status in MDS

Patients with myelodysplastic syndrome harboring a TP53 mutation experienced a survival benefit with allogeneic hematopoietic cell transplantation compared with non-HCT treatment regardless of TP53 allelic status. ....

Molecular International Prognostic Scoring System , International Prostate Symptom Score , Marrow Transplant Clinical Trials Network , Myeloproliferative Neoplasms , Myelodysplastic Syndrome ,